Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial.

Purpose: The CLL12 trial reassesses the watch-and-wait consensus for early-stage chronic lymphocytic leukemia (CLL) in the context of targeted therapies.

Methods: The German CLL Study Group conducted a randomized, double-blind, placebo-controlled phase III trial with 363 patients with asymptomatic, treatment-naïve Binet stage A CLL at increased risk of progression to receive ibrutinib (n = 182) at a daily dose of 420 mg or placebo (n = 181). Additionally, 152 low-risk patients were allocated to the watch-and-wait group.

[Hepatotoxicity due to albendazole: safe alternatives for echinococcosis therapy].

Infection with Echinococcus multilocularis leads to the clinical manifestation of alveolar echinococcosis. This is characterized by the formation of alveolar liver tumours, which usually disintegrate necrotically in the course of the disease. Pseudocysts are formed.

Controlling conjugated polymer morphology by precise oxygen position in single-ether side chains.

Recently, polar side chains have emerged as a functional tool to enhance conjugated polymer doping properties by improving the polymer miscibility with polar chemical dopants and facilitate solvated ion uptake. In this work, we design and investigate a novel family of side chains containing a single ether function, enabling the modulation of the oxygen atom position along the side chain. A meticulous investigation of this new polymer series by differential scanning calorimetry, fast scanning chip calorimetry and X-ray scattering shows that polymers bearing single-ether side chains can show high degree of crystallinity under proper conditions.